about
Evaluation and management of overactive bladder: strategies for optimizing careLocal Oestrogen for Pelvic Floor Disorders: A Systematic ReviewA clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapyPostmenopausal overactive bladderRegulation of Guinea Pig Detrusor Smooth Muscle Excitability by 17β-Estradiol: The Role of the Large Conductance Voltage- and Ca2+-Activated K+ Channels.Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence.Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy TreatmentPositive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in TaiwanThe role of local estrogen therapy in the management of pelvic floor disorders.What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014.Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014.Prevention of pelvic floor disorders: international urogynecological association research and development committee opinion.Safety issues associated with using medication to treat overactive bladder.Topographies and isoforms of the progesterone receptor in female human, rat and mouse bladder.Nongenomic modulation of the large conductance voltage- and Ca2+-activated K+ channels by estrogen: A novel regulatory mechanism in human detrusor smooth muscleDevelopment of a core set of outcome measures for OAB treatment.Medication use and association with urinary incontinence in women: Data from the Norwegian Prescription Database and the HUNT study.Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.
P2860
Q26739217-E14E2F85-7A81-4FA2-B54A-9AE2A3E12D9AQ26783453-E3B8C630-095D-46A3-BD40-28C923DC979CQ33605919-44447FDB-21E5-4A30-9DC6-685C6652D2D5Q35157329-20626DD4-8E06-4722-83FE-F896EB80ADB4Q35831908-9778CED1-EA3F-4C5B-AFE4-2214B07B48C1Q36096914-B32FBA53-F049-44B6-A59A-FE36F2BB8D11Q37034036-C37383FB-203B-4B3F-B9AC-8BA3FC65E1ACQ37116772-01222CEC-5DE1-4C64-952B-945734234562Q38717871-C220193E-6FC8-42AE-A163-73E118289778Q38731389-5FCAB896-13F4-47F0-9E53-279BE60F9E6EQ38731395-1FBEA1E1-6A67-48D9-914C-6DABA66CECEBQ38771985-C3147009-9937-42AA-8785-3AE8DFC92A80Q40058585-8440E355-C7A1-43A6-98C8-A96990E40932Q40229103-96AE69FA-3B31-4556-B98A-BF14B772F4FAQ41160541-FA3B2B73-AACE-467A-8A09-DD1DA19BECC2Q47095229-D31614B8-627B-4E97-A1F9-134104DED1A7Q47555554-814E4089-4C3C-4C2D-B72E-85A707605496Q53496298-658883DB-2F33-46FA-A939-7B5576D7D454
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Oestrogens and overactive bladder.
@en
type
label
Oestrogens and overactive bladder.
@en
prefLabel
Oestrogens and overactive bladder.
@en
P2093
P2860
P356
P1476
Oestrogens and overactive bladder.
@en
P2093
Dudley Robinson
Heinz Koelbl
Ian Milsom
Linda Cardozo
Mark Vierhout
Michael Kirby
Montserrat Espuna Pons
P2860
P304
P356
10.1002/NAU.22464
P577
2013-07-19T00:00:00Z